Express Healthcare

MedSign raises seed funding from SMSRC

0 490

MedSign aims to improve patient outcomes by improving accessibility of real-time, comprehensive, transferrable and transparent patients’ health records at the point-of-care and improving continuity of care

Bengaluru-based healthtech startup MedSign has announced that it has raised an undisclosed amount as a seed fund from SMSRC, a leading strategic advisor and research catering to the pharma industry in India and Bangladesh, as a part of its strategic collaboration.

Founded in 2018, MedSign aims to improve patient outcomes by improving accessibility of real-time, comprehensive, transferrable and transparent patients’ health records at the point-of-care and improving continuity of care.

Speaking on the investment, Shrihari Shidhaye, Founder-Director, MedSign, said, “As we embark on our next level of growth, this seed funding from SMSRC will help us strengthen our offerings to the market and thereby enhance patient care by digitising patients’ health journey to create a comprehensive digital medical database, that is secure, easily accessible and real-time for clinicians and patients. Further, SMSRC’s widespread existing doctor network and relationships across the healthcare ecosystem will be an important avenue towards rapid penetration of MedSign. We also plan to raise additional funds to fuel our growth and expansion plans.”

Adding to it, Dr Sanjoy Mitra, MD and Founder, SMSRC, said, “We are delighted to be a part of MedSign’s growing journey. Driving innovation in healthcare research through technology has been a key motive of SMSRC, since inception. Unlike many other healthtech startups in the country with a myriad of objectives, MedSign’s primary area of focus is doctors, with relevant products for both doctors and patients. We are confident about the uniqueness of the MedSign platform, and that has already received rave reviews from multiple stakeholders.”

Since going to market in January 2020, MedSign has over 1300 multi-speciality doctors and more than 19,000 patients.

- Advertisement -

Leave A Reply

Your email address will not be published.